Can a Triple-Action antibody deepen remissions in myeloma?

This phase II trial is testing whether a new investigational drug called IBI3003, when combined with an existing anti-CD38 antibody (daratumumab), can improve outcomes for people with multiple myeloma. The study includes patients with relapsed or refractory disease, as well as newly diagnosed patients who are either eligible or ineligible for stem cell transplantation. The main goal is to see if this combination can achieve a high rate of minimal residual disease (MRD) negativity at 24 weeks, which indicates a very deep level of remission.